|
|
|
|
|
|
Corporate Strategy: Working with the executive team of a large company,
Health Advances led a board-mandated review of the strategic positioning and business options
for two divisions within the company, diagnostics products and life science products. In addition
to a thorough assessment of internal strengths and weaknesses, we also examined the competitive environment,
trends with customers, our clients’ position and the options for expanding the business internally and through acquisition.
Value-Based Pricing and Reimbursement: Health Advances worked with an oncology diagnostics company to conduct a system
economics analysis for a novel test for staging a certain type of cancer. Detailed secondary research and a thorough primary research
program with physicians, payers, and coders across the US assisted in the generation of a fact-based economic model detailing the costs
associated with diagnosis and treatment. A value based price for the new test was determined based on the cost savings and quality adjusted
life years gained from using the test.
Therapeutic Response Prediction: Health Advances evaluated the potential for a predictive diagnostic to assist oncologists in making treatment
decisions for breast, colon and lung cancer. Market potential was determined through performance of a conjoint analysis as well as a survey to
tie product preferences to actual market share. A development strategy was performed based on the current status of assay development in different
indications combined with necessary attributes for market success in each patient population.
Application Identification for a Platform Technology: Health Advances assessed the clinical diagnostics market to determine the most favorable applications
for a novel detection platform. Ideal clinical applications were identified from a broad screen of known biomarkers and aligned with both the platform’s
technical capabilities and the company’s strategic goals. Detailed analyses of these opportunities including top level value based pricing and test volume
estimates were performed. Working with the senior management team, we developed a commercialization strategy to maximize adoption of the platform in several
point-of-care settings including the primary care physician’s office.
Point-of-Care Testing Strategy: Health Advances worked with a large diagnostics company to develop a global point-of-care diagnostics strategy including both
the developed and developing worlds. The key area of focus was infectious disease. To evaluate the potential of a new detection technology, we performed
interviews with primary care physicians, infectious disease experts, policy makers at non-governmental organizations, and payers, as well as extensive
secondary literature review to assess the competitive landscape. A detailed forecast model was developed for a number of applications.
Deal Terms and Partnering Strategy: Health Advances worked with a large European company to investigate the range of potential deal terms it could achieve
with a large US therapeutics company for its novel cancer diagnostic platform. All cancer diagnostics deals within the past 5 years were analyzed to determine
the range of upfront, milestone, and royalty payments. Specific deals were outlined to extract more insights into potential partners for the client.
|
|
 |
|
|
|
|
